Remibrutinib for Chronic Itch

This trial tests a new treatment called remibrutinib for individuals with severe chronic itch of unknown cause. The primary goal is to determine if this treatment is safe and effective in reducing symptoms. Participants will either receive remibrutinib directly or start with a placebo (a pill resembling the real medication but containing no active ingredients) before switching to remibrutinib later. This study targets adults who have experienced a severe, persistent itch on their trunk, arms, or legs for at least four months, despite using creams or ointments. As a Phase 3 trial, it represents the final step before FDA approval, offering participants the opportunity to contribute to a potentially groundbreaking treatment.

The trial protocol does not specify if you need to stop taking your current medications. However, if you are on dual anti-platelet therapy, you cannot participate in the trial.

Research has shown that remibrutinib is generally safe for people. Studies involving patients with chronic spontaneous urticaria (a type of hives) indicate that most users tolerate the treatment well.

In one study, remibrutinib did not cause any major safety issues over a year, and patients' liver function remained stable. Another study found that the number of unwanted side effects was similar between those taking remibrutinib and those taking a placebo, indicating that serious side effects are rare.

Unlike the standard treatments for chronic itch, which often involve topical steroids or antihistamines, remibrutinib is unique because it targets a different pathway in the body. Most traditional options work by suppressing inflammation or blocking histamine, but remibrutinib works by inhibiting Bruton’s tyrosine kinase (BTK), an enzyme involved in the immune response linked to itch. Researchers are excited about remibrutinib because this novel mechanism may offer relief for patients who don't respond well to existing therapies, potentially providing a new option for managing chronic itch more effectively. Additionally, the trial includes a placebo group that switches to remibrutinib, allowing scientists to better understand its long-term benefits and safety.

Research has shown that remibrutinib can help reduce chronic itching. In earlier studies with patients who had similar conditions, many experienced improvements in just one week. After 52 weeks, over half of the patients achieved complete relief from their symptoms. The treatment was generally safe and well-tolerated. In this trial, participants will receive either remibrutinib or a placebo followed by remibrutinib. These findings suggest that remibrutinib could effectively manage severe chronic itching of unknown cause.¹²⁶⁷⁸